Molecure

We are pleased to announce another important milestone in the clinical development of 📣

has completed the dose-limiting toxicity (DLT) observation period in all patients treated with OATD-02 at the 40 mg QD dose level. Following review of the data collected so far, and with approval from the Safety Review Committee (SRC), the study has progressed to the 80 mg QD dose level.

Importantly, the data confirmed therapeutic target engagement - a key step toward identifying the pharmacologically active dose of our investigational arginase inhibitor. continues to advance in Phase 1 clinical development as a potential novel therapy in oncology! 🌍

We are pleased to announce that has been granted a US patent (US12612420 (B2)) for the latest series of arginase inhibitors! 📣

These inhibitors are backup compounds for , a frontrunner that is performing well in Phase 1 clinical trials (NCT05759923, https://clinicaltrials.gov/study/NCT05759923?term=oatd-02&viewType=Card&rank=1). This achievement underscores Molecure's global leadership in the field of arginase inhibitors 🌍

➡️Link to the patent: https://worldwide.espacenet.com/patent/search/family/079287969/publication/US12612420B2?q=pn%3DUS12612420B2

We are excited to share that our team members, Theodoros Charitos (Medical Director) and Katarzyna Drzewicka (Head of Early Discovery), are attending the International Conference in Orlando, FL (US) 🇺🇸

Our team, along with renowned co-authoring pulmonology and nuclear medicine clinicians, is showcasing the Phase 2 Study in pulmonary sarcoidosis and highlighting ’s ongoing work on . This abstract, in form of a poster, presents approaches to evaluating treatment response using advanced PET imaging methodologies. It is presented in the scientific session dedicated to biomarkers, imaging, and physiology in Interstitial Lung Diseases (ILDs) taking place today, May 20th, 2026. Its title is “Novel Semi-quantitative Fluorodeoxyglucose Positron Emission Tomography Response Criteria as Primary Endpoint in Pulmonary Sarcoidosis: Methodological Design and Implementation in the KITE Phase 2 Study” 🔬

Molecure team is proud to be part of the global scientific community efforts around innovative therapies for pulmonary diseases including ILDs/pulmonary sarcoidosis 🌍

🎙️ Our CEO, Marcin Szumowski, joined inwestorzy.tv, where he spoke about ’s key priorities, including progress in the study for , ongoing partnering discussions, and the potential of projects developed in inflammatory and oncology diseases 🔬

The interview also highlights the company’s development outlook and upcoming milestones important for investors following the biotech sector 📈

➡️ Watch the full interview here: https://www.youtube.com/watch?v=7j4Bjn0zH3k&feature=youtu.be

, in collaboration with and , explores targeting ubiquitin-specific protease 7 ( ) 📖

is a deubiquitinating enzyme frequently overexpressed in cancer and linked to stabilization of oncogenic proteins and immunosuppressive factors. Structure-guided discovery and SAR-driven optimization efforts yielded selective USP7 inhibitors to explore this therapeutic target, with OAT-4828 emerging as a potent lead compound. The screening cascade, which led to the discovery of OAT-4828 incorporated cellular system, including primary T cells, where the compound increased T-cell killing capacity without causing toxicity – highlighting a scientifically new role of USP7 in immune cell activation. The pharmacokinetic profile in mice and preliminary safety assessments of OAT-4828 enabled in vivo studies. OAT-4828 was well-tolerated in mice, demonstrating significant antileukemic activity in a syngeneic model of B-cell derived non-Hodgkin lymphoma without systemic toxicity.

One of the key substrates regulated by USP7 is . With several MDM2 inhibitors currently in clinical development, the p53-MDM2 axis is firmly validated as a critical therapeutic target. Our latest research highlights how USP7 inhibition may offer a powerful, upstream approach to modulate this proven pathway.

Read more ➡️ https://pubs.acs.org/doi/10.1021/acs.jmedchem.6c00407

We are proud to share that our R&D Operations Director, Barbara Dymek, has been nominated to the TOP 100 Women in Biotech in Poland ranking by Perspektywy Women in Tech 👩‍⚕️

This prestigious recognition highlights outstanding female leaders shaping the future of biotechnology and inspiring the next generation in a field where women’s representation remains especially important.

The winners will be selected by an esteemed jury, with the official announcement and the Excellence in Biotech Awards ceremony taking place on June 10-11 during the Perspektywy Women in Tech Summit 2026 in Warsaw 🥇

More information: https://womenintechsummit.pl/top-100-women

Congratulations on this well-deserved nomination! 🎉

We were proud to have our team represented by Piotr Iwanowski (CMO), Theodoros Charitos (Medical Director) and Geolyce Mpofu (Director, Patient Recruitment and Site Engagement) at the 5th National Conference on Diagnosis and Treatment: Evolution and New Paradigms, held in Rome, Italy on April 17-18, 2026 and organized by ACSI - Amici Contro la Sarcoidosi Italia.

During the conference, our team shared insights on the ongoing Phase II study, evaluating in patients with active pulmonary sarcoidosis. It was a valuable opportunity to engage with clinicians, researchers, and the wider sarcoidosis community, and to contribute to the evolving conversation around new therapeutic approaches 🔬

It’s Sarcoidosis Awareness Month! 💜 This month, we stand with the global sarcoidosis community to raise awareness of this rare and often under-recognized disease.

At , we are proud to support the Foundation for Sarcoidosis Research ( ) and their campaign - uniting voices worldwide to increase visibility, understanding, and hope for patients living with sarcoidosis.

As part of our commitment to advancing science in this area, we are developing , a first-in-class CHIT1 inhibitor, currently in Phase II clinical trials ( ) in patients with active pulmonary sarcoidosis

Join us this month in raising awareness and supporting everyone affected by sarcoidosis 💜

has secured funding from the European Union for the project titled: “Preparation of the Eurogrant application planned to be implemented under the EIC Accelerator Open 2025 programme”, under Measure 02.12 “Grants for Eurogrants”, financed by the European Funds for a Modern Economy 2021-2027 programme. The grant agreement no. FENG.02.12-IP.02-0436/25 was signed on 30 March 2026.

The objective of the Project is to prepare an application for a Eurogrant under the Horizon Europe Framework Programme, within the EIC Accelerator Open call (https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/HORIZON-EIC-2026-ACCELERATOR-01), organised and centrally managed by the European Innovation Council and SMEs Executive Agency (EISMEA). The EIC Accelerator programme supports deep-tech innovations at TRL levels 6-9.

Scope of the Eurogrant: Preparation of the small-molecule drug candidate OATD-01 and its clinical development programme for the initiation of Phase III trials in the treatment of pulmonary sarcoidosis, as well as the development of strategic partnerships with pharmaceutical companies to enable the delivery of this breakthrough therapy to patients.

The Project result assumes the completion of the application evaluation process and obtaining a minimum score of 6/9 (“GO”) at the full application stage.



Project value: PLN 69,412.00
EU funding contribution: PLN 69,412.00
Project implementation period: 01.08.2025 - 31.12.2026

Hello from Lisbon! ☀️

Our team: Marcin Szumowski (CEO), Zbigniew Zasłona (CSO) and Maurycy Zieliński (Business Development Director), is currently attending Spring 2026 in Portugal 🇵🇹

Great conversations and meaningful connections at - a valuable opportunity to engage with global biotech and pharma innovators, share perspectives and highlight ’s ongoing work on novel therapeutic solutions 🧬